Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Condition: Multiple Myeloma
MeSH terms: Multiple Myeloma; Neoplasms, Plasma Cell
Intervention: Bortezomib; Granulocyte colony-stimulating factor (G-CSF); Mozobil
Intervention description: Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.; Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.; Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
Intervention MeSH terms: Plerixafor; Bortezomib; Lenograstim
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 101.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Multiple Myeloma; Bortezomib; Autologous; Stem Cell; Purging; In-vivo purging; Ex-vivo purging; Leukapheresis; Contaminated; Stem Cell Harvest; Stem Cell Transplant; Transplantation

Summary:

      Explore stem cell collection with or without bortezomib with in-vivo purging in multiple
      myeloma.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must meet all of the inclusion criteria to participate in this study.

          -  Ability to understand, and the willingness to sign a written Informed Consent Form

          -  Diagnosis of multiple myeloma undergoing planned autologous stem cell transplantation

          -  Age ≥ 18 years

          -  Karnofsky Performance Status (KPS) 70 or above, Eastern Cooperative Oncology Group
             (ECOG) 0, 1 or 2

          -  Adequate organ and marrow function as defined below:

               -  leukocytes ≥ 3,000/micro Liter (mcL)

               -  absolute neutrophil count ≥ 1,500/mcL

               -  platelets ≥ 100,000/mcL

               -  total bilirubin within normal institutional limits NOTE: For this study, subjects
                  with bilirubin levels > 1.5 Upper Limit of Normal (ULN) are excluded from
                  enrollment in this study.

               -  Aspartate Aminotransferase (AST) ( Serum Glutamic Oxaloacetic Transaminase
                  [SGOT]) ≤ 2.5 X institutional upper limit of normal

               -  Alanine Aminotransferase (ALT) (Serum Pyruvic Glutamic Transaminase [SPGT]) ≤ 2.5
                  X institutional upper limit of normal

               -  creatinine within normal institutional limits

          -  Women of child-bearing potential and men with partners of child-bearing potential must
             agree to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry, for the duration of study participation, and for 30
             days following completion of therapy. Should a woman or partner become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician and the investigator immediately.

          -  A woman of child-bearing potential is any female (regardless of sexual orientation,
             having undergone a tubal ligation, or remaining celibate by choice) who meets the
             following criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy; or

               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
                  has had menses at any time in the preceding 12 consecutive months)

        Exclusion Criteria:

          -  Subjects meeting any of the exclusion criteria at baseline will be excluded from study
             participation.

          -  Current or anticipated use of other investigational agents. NOTE the following
             clarification for this study: Prohibited Concurrent Therapy:

        Participation in clinical trials with other investigational agents that are not included in
        this trial, within 14 days of the start of this trial until 2 weeks after participant has
        received the last dose of bortezomib for mobilization.

          -  Hypersensitivity to bortezomib, boron or mannitol or Granulocyte colony-stimulating
             factor (G-CSF)

          -  Subject has received > 6 months of lenalidomide (Revlimid®) therapy prior to stem cell
             collection

          -  Subject has known brain metastases. Presence of brain metastases should be excluded
             from this clinical trial because of poor prognosis and because patients often develop
             progressive neurologic dysfunction that would confound the evaluation of neurologic
             and other adverse events.

          -  Grade 3 or higher peripheral neuropathy

          -  Bilirubin levels > 1.5 ULN

          -  Uncontrolled inter-current illness including, but not limited to

               -  ongoing or active infection

               -  symptomatic congestive heart failure

               -  unstable angina pectoris

               -  cardiac arrhythmia

               -  psychiatric illness/social situations that would limit compliance with study
                  requirements

          -  Pregnant or nursing: There is a potential for congenital abnormalities and for this
             regimen to harm nursing infants.